Virtu Financial LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Virtu Financial LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 15,214 shares of the medical device company’s stock, valued at approximately $1,020,000.

A number of other hedge funds have also modified their holdings of DXCM. Toronto Dominion Bank boosted its position in DexCom by 3.1% in the third quarter. Toronto Dominion Bank now owns 204,522 shares of the medical device company’s stock valued at $13,711,000 after buying an additional 6,227 shares during the last quarter. Coldstream Capital Management Inc. raised its position in DexCom by 45.3% during the 3rd quarter. Coldstream Capital Management Inc. now owns 11,253 shares of the medical device company’s stock worth $781,000 after buying an additional 3,508 shares during the last quarter. Geode Capital Management LLC lifted its stake in DexCom by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 9,937,604 shares of the medical device company’s stock valued at $664,056,000 after acquiring an additional 214,136 shares during the period. Brophy Wealth Management LLC purchased a new stake in shares of DexCom in the 3rd quarter valued at $337,000. Finally, LRI Investments LLC boosted its holdings in shares of DexCom by 225.0% in the 3rd quarter. LRI Investments LLC now owns 8,454 shares of the medical device company’s stock valued at $567,000 after acquiring an additional 5,853 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on DXCM. Raymond James reduced their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Wells Fargo & Company lifted their price objective on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Piper Sandler reissued an “overweight” rating and issued a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

DexCom Stock Down 2.2 %

Shares of NASDAQ DXCM opened at $77.19 on Friday. The firm has a market cap of $30.15 billion, a price-to-earnings ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The company’s 50-day simple moving average is $73.58 and its 200-day simple moving average is $84.99. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.